Yonhap Infomax NewsYuhan Corporation's lung cancer drug Leclaza combination therapy receives approval as first-line treatment in Japan, marking significant milestone for Korean pharmaceutical industry
#YonhapInfomax #YuhanCorporation #Leclaza #LungCancerDrug #JapanApproval #FirstLineTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56147
#YonhapInfomax #YuhanCorporation #Leclaza #LungCancerDrug #JapanApproval #FirstLineTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56147
Yuhan Corporation's Lung Cancer Drug Leclaza Combination Therapy Approved as First-Line Treatment in Japan
Yuhan Corporation's lung cancer drug Leclaza combination therapy receives approval as first-line treatment in Japan, marking significant milestone for Korean pharmaceutical industry